PXD041824 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition |
Description | High-risk neuroblastoma (NB) currently presents significant clinical challenges. MYCN and ALK, which are often involved in high-risk NB, lead to increased replication stress in cancer cells, providing options for therapeutic exploitation. We previously identified an ATR/ALK inhibitor combination as an effective therapeutic approach in two independent genetically modified mouse NB models. Here, we identify an underlying molecular mechanism, in which ALK signalling leads to phosphorylation of ATR and CHK1, supporting an effective DNA damage response. The importance of ALK inhibition is supported by mouse data, in which monotreatment with ATRi resulted in a robust initial response, but subsequent relapse, in contrast to a 14-day ALKi/ATRi combination treatment that resulted in robust and sustained responses. Finally, we show that the remarkable response to the 14-day combined ATR/ALK inhibition protocol reflects a robust differentiation response in the tumour, reprogramming tumour cells to a neuronal/Schwann cell lineage identity. Our results identify a unique ability of ATR inhibition to trigger neuroblastoma differentiation and underscore the importance of further exploring combined ALK/ATR inhibition in NB, particularly in high-risk patient groups with oncogene-induced replication stress. |
HostingRepository | PRIDE |
AnnounceDate | 2023-12-13 |
AnnouncementXML | Submission_2023-12-13_05:52:36.552.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Evelin Berger |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | methylthiolated residue; phosphorylated residue; monohydroxylated residue |
Instrument | Orbitrap Fusion Lumos |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-04-26 05:48:31 | ID requested | |
⏵ 1 | 2023-12-13 05:52:36 | announced | |
Publication List
Dataset with its publication pending |
Keyword List
submitter keyword: ALK, ATR, elimusertib, neuroblastoma, lorlatinib, ALKAL, DDR, ceralasertib |
Contact List
Carina Sihlbom |
contact affiliation | Proteomics Core Facility University of Gothenburg Sweden |
contact email | carina.sihlbom@gu.se |
lab head | |
Evelin Berger |
contact affiliation | University of Gothenburg |
contact email | evelin.berger@gu.se |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/12/PXD041824 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD041824
- Label: PRIDE project
- Name: ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition